2024 has started off with a bang with recent back-to-back positive results for gene therapy for rare genetic hearing disorders and major headways in otoprotective, restorative and regenerative smal
Returning for a third year, the mRNA-Based Therapeutics Summit is the world’s only end-to-end meeting focused on the next generation of mRNA-based therapeutics and vaccines, and provides th
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.